Axoltis Pharma

ALS concept
#ALS #Axoltis Pharma #Financing

Axoltis Pharma raises €18 million to advance ALS drug 

Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round… Read More

#Business & Investment #News

Brain inflammation
#Amyotrophic lateral sclerosis (ALS) #Axoltis Pharma #Blood brain barrier #Clinical trials #Neuroscience #Regulatory

Drug candidate for ALS patients authorised for Phase II trial

Axoltis Pharma has received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for Amyotrophic Lateral Sclerosis (ALS).   This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of… Read More

#News #Regulatory